Literature DB >> 12885787

Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship.

Iain A Sharpe1, Elka Palant, Christina I Schroeder, David M Kaye, David J Adams, Paul F Alewood, Richard J Lewis.   

Abstract

chi-Conopeptide MrIA (chi-MrIA) is a 13-residue peptide contained in the venom of the predatory marine snail Conus marmoreus that has been found to inhibit the norepinephrine transporter (NET). We investigated whether chi-MrIA targeted the other members of the monoamine transporter family and found no effect of the peptide (100 microM) on the activity of the dopamine transporter and the serotonin transporter, indicating a high specificity of action. The binding of the NET inhibitors, [3H]nisoxetine and [3H]mazindol, to the expressed rat and human NET was inhibited by chi-MrIA with the conopeptide displaying a slight preference toward the rat isoform. For both radioligands, saturation binding studies showed that the inhibition by chi-MrIA was competitive in nature. It has previously been demonstrated that chi-MrIA does not compete with norepinephrine, unlike classically described NET inhibitors such as nisoxetine and mazindol that do. This pattern of behavior implies that the binding site for chi-MrIA on the NET overlaps the antidepressant binding site and is wholly distinct from the substrate binding site. The inhibitory effect of chi-MrIA was found to be dependent on Na+ with the conopeptide becoming a less effective blocker of [3H]norepinephrine by the NET under the conditions of reduced extracellular Na+. In this respect, chi-MrIA is similar to the antidepressant inhibitors of the NET. The structure-activity relationship of chi-MrIA was investigated by alanine scanning. Four residues in the first cysteine-bracketed loop of chi-MrIA and a His in loop 2 played a dominant role in the interaction between chi-MrIA and the NET. H alpha chemical shift comparisons indicated that side-chain interactions at these key positions were structurally perturbed by the replacement of Gly-6. From these data, we present a model of the structure of chi-MrIA that shows the relative orientation of the key binding residues. This model provides a new molecular caliper for probing the structure of the NET.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885787     DOI: 10.1074/jbc.M213030200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.

Authors:  Juan Zhen; Solav Ali; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

Review 2.  Marine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action.

Authors:  Alejandro M S Mayer; Abimael D Rodríguez; Roberto G S Berlinck; Mark T Hamann
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2007-02-09       Impact factor: 3.228

3.  Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties.

Authors:  Pieter Okkerse; Justin L Hay; Elske Sitsen; Albert Dahan; Erica Klaassen; William Houghton; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2016-12-16       Impact factor: 4.335

4.  Determinants of alpha-conotoxin BuIA selectivity on the nicotinic acetylcholine receptor beta subunit.

Authors:  David L Shiembob; Ryan L Roberts; Charles W Luetje; J Michael McIntosh
Journal:  Biochemistry       Date:  2006-09-19       Impact factor: 3.162

5.  A novel conotoxin, qc16a, with a unique cysteine framework and folding.

Authors:  Mingyu Ye; Jing Hong; Mi Zhou; Lijun Huang; Xiaoxia Shao; Youshan Yang; Fred J Sigworth; Chengwu Chi; Donghai Lin; Chunguang Wang
Journal:  Peptides       Date:  2011-04-15       Impact factor: 3.750

6.  Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram.

Authors:  Jean D Deupree; Megan D Montgomery; David B Bylund
Journal:  Eur J Pharmacol       Date:  2007-08-23       Impact factor: 4.432

7.  Bioactive marine drugs and marine biomaterials for brain diseases.

Authors:  Clara Grosso; Patrícia Valentão; Federico Ferreres; Paula B Andrade
Journal:  Mar Drugs       Date:  2014-05-02       Impact factor: 5.118

8.  Animal protein toxins: origins and therapeutic applications.

Authors:  Na Chen; Siqi Xu; Yuhan Zhang; Feng Wang
Journal:  Biophys Rep       Date:  2018-10-11

Review 9.  Scorpion toxins specific for potassium (K+) channels: a historical overview of peptide bioengineering.

Authors:  Zachary L Bergeron; Jon-Paul Bingham
Journal:  Toxins (Basel)       Date:  2012-11-01       Impact factor: 4.546

Review 10.  Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development.

Authors:  David J Newman; Gordon M Cragg
Journal:  Mar Drugs       Date:  2014-01-14       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.